Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus bevacizumab as first-line treatment for advanced vascular sarcomas and related tumors
ChiCTR2300077682Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and bevacizumab in angiosarcoma, epithelioid hemangioendothelioma (EHE), malignant solitary fibrous tumor (SFT) and 1 more, sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Started Nov 2023; status: recruiting.
02
Drugs
paclitaxelbevacizumab
03
Conditions
angiosarcomaepithelioid hemangioendothelioma (EHE)malignant solitary fibrous tumor (SFT)hemangiopericytoma (HPC)
Beyond the preview
Go deeper on ChiCTR2300077682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077682.